High-efficacy disease-modifying therapies despite clinical stability: the role of patients on treatment decisions (PERCEPTIONS-MS Study)

被引：0
|
作者：
Saposnik, G. [1 ,2 ,3 ]
Sempere, A. P. [4 ]
Aladro-Benito, Y. [5 ]
Sotoca, J. [6 ]
Bakdache, F. [7 ]
Terzaghi, M. [2 ,8 ]
Maurino, J. [9 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Dept Med, Div Neurol, Toronto, ON, Canada
[2] St Michaels Hosp, Decis Neurosci Unit, Toronto, ON, Canada
[3] Univ Zurich, Lab Social & Neural Syst Res, Dept Econ, Zurich, Switzerland
[4] Hosp Gen Univ Alicante, Dept Neurol, Alicante, Spain
[5] Hosp Univ Getafe, Dept Neurol, Getafe, Spain
[6] Hosp Univ Mutua Terrassa, Dept Neurol, Terrassa, Spain
[7] Hoffmann La Roche Ltd, Neurosci, Med Affairs, Mississauga, ON, Canada
[8] Univ Toronto, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[9] Roche Farma SA, Med Dept, Madrid, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1433
引用
收藏
页码：800 / 800
页数：1
相关论文
共 50 条
  • [31] Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
    Katarzyna Śladowska
    Paweł Kawalec
    Przemysław Holko
    Oktawia Osiecka
    Neurological Sciences, 2022, 43 (9) : 5479 - 5500
  • [32] Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis
    Mariottini, Alice
    Nozzoli, Chiara
    Carli, Ilaria
    Landi, Filippo
    Gigli, Valentina
    Repice, Anna Maria
    Ipponi, Alessandra
    Cecchi, Michele
    Boncompagni, Riccardo
    Saccardi, Riccardo
    Massacesi, Luca
    NEUROLOGICAL SCIENCES, 2024, 45 (07) : 3379 - 3387
  • [33] The CLARITY study: efficacy outcomes among patients who received disease-modifying therapies prior to treatment with cladribine tablets
    Vermersch, P.
    Rammohan, K.
    Damian, D.
    Jack, D.
    Harty, G.
    Wong, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 301 - 302
  • [34] Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Magalashvili, David
    Sonis, Polina
    Dolev, Mark
    Menascu, Shay
    Flechter, Shlomo
    Falb, Rina
    Gurevich, Michael
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [35] REAL-WORLD DISCONTINUATION OF HIGH-EFFICACY DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS: A TARGETED LITERATURE REVIEW
    Miller, A.
    Veenstra, D.
    Bansal, A.
    VALUE IN HEALTH, 2024, 27 (06) : S327 - S327
  • [36] Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
    Sladowska, Katarzyna
    Kawalec, Pawel
    Holko, Przemyslaw
    Osiecka, Oktawia
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5479 - 5500
  • [37] Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis
    Silva, Guilherme Diogo
    Castrillo, Bruno Batitucci
    Apostolos-Pereira, Samira Luisa
    Callegaro, Dagoberto
    ACTA NEUROLOGICA SCANDINAVICA, 2022, 146 (05): : 403 - 409
  • [38] The Effect of Demographic Factors on Prescription of High-Efficacy Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis (P1-1.Virtual)
    Grimshaw, Jack
    Mallawaarachchi, Gagana
    Jackson, Thomas
    Das, Joyutpal
    Rog, David
    NEUROLOGY, 2022, 98 (18)
  • [39] Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies
    Sahloul, Oussama
    Louapre, Celine
    Beigneux, Ysoline
    Lubetzki, Catherine
    Maillart, Elisabeth
    Roux, Thomas
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 85
  • [40] Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
    Habek, Mario
    Brecl, Gregor Jakob
    Kes, Vanja Basic
    Rogic, Dunja
    Barun, Barbara
    Gabelic, Tereza
    Emersic, Andreja
    Ledinek, Alenka Horvat
    Grbic, Nevena
    Lapic, Ivana
    Segulja, Dragana
    Duric, Koraljka
    Adamec, Ivan
    Skoric, Magdalena Krbot
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 359
12345